Akèy › Kasinòm epitelyal ovè › Ohio
Etid klinik pou Kasinòm epitelyal ovè nan Ohio
10 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
- Research Site, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Oct 1, 2026 · NCT07851025A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
- Cleveland Clinic - Cleveland /ID# 276133, Cleveland
- Cleveland Clinic - Cleveland /ID# 278273, Cleveland
- ak 3 plis
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Sep 29, 2026 · NCT06890338Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05867251ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT05059444Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer
- Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland
Ap rekrite
Laj 18 ak plis · Fanm · Mizajou Aug 6, 2026 · NCT06386887AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Blue Ash
- Research Site, Dayton
- Research Site, Sylvania
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Miami Valley Hospital South, Centerville
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Stefanie Spielman Comprehensive Breast Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06395519CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- The James Cancer Hospital and Solove Research Institute - Ohio State University, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou Dec 23, 2025 · NCT06690775Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.